

Fig. S1: Immunoflourescent localization of HA-BcI-xL. KB-3/HA-BcI-xL cells were fixed and permeabilized. Mitochondria (red signal, left panel) was visualized with Mitotracker Red, and BcI-xL (green signal, center panel) was localized by probing with rabbit polyclonal BcI-xL antibody and FITC goat anti-rabbit secondary antibody. Right panel, overlay image.



Fig. S2:HA-Bcl-xL undergoes vinblastine-induced phosphorylation. A, KB-3 or KB-3/HA-Bcl-xL cells were untreated or treated with vinblastine (VBL; 30 nM) and extracts (50 μ g) subjected to immunoblotting with Bcl-xL antibody. B, KB-3/HA-Bcl-xL cells were either untreated or treated with 30 or 200 nM VBL (16 h) and 3 μ g protein/lane analyzed for HA immunoreactivity by blotting. "Mix" indicates a mixture of samples prepared from cells at 0 and 200 nM VBL.



Fig. S3: Quantitative immunoprecipitation of BcI-xL. Extracts (Ext.) were prepared from untreated or vinblastine (VBL, 200 nM) treated KB-3/HA-BcI-xL cells and 1 mg aliquots were subjected to incubation with increasing concentrations of rabbit BcI-xL antibody as indicated. Immunoprecipitates (P) and supernatants (S) were immunoblotted with mouse monoclonal BcI-xL antibody. "No Ab" indicates immunoprecipitation conducted in the absence of antibody.





Fig. S4:Tandem mass spectrometric analysis mapping the single phosphorylation site Ser62 (underlined) in phosphopeptide 61-75. A, The signature phosphopeptide neutral loss of 98 Da from the parent ion is indicated. Fragment ions containing the phosphorylated amino acid will have a mass addition of 80 Da. Peptide deamidation was mapped to Asn66. **B**, MALDI-MS3 analysis of the -98Da fragment from vinblastine-treated HA-Bcl-xL phosphopeptide 61-75 provided further confirmation that Ser62 was phosphorylated and Asn66 was deamidated. Fragment ions that contained the phosphorylated amino acid will show an 18 Da mass loss.



Fig. S5: Ser62 to Ala mutation of Bcl-xL does not alter mitotic arrest caused by vinblastine treatment. KB-3 cells or cell lines overexpressing wild-type Bcl-xL, Bcl-xL(S62A) or Bcl-xL(T47A) (2 clones of each) were untreated or treated with 30 nM vinblastine (VBL) for 16 h and cell extracts subjected to immunoblotting for cyclin B